B and T cells in chronic graft-versus-host disease and graft-versus-leukemia - Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation - page 319

[96] Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of
chronic graft-versus-host disease: contribution to improved survival after allogeneic
marrow transplantation. N Engl J Med 1981;304:1529-33.
[97] Truitt RL, Atasoylu AA. Contribution of CD4+ and CD8+ T cells to graft-versus-host
disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible
bone marrow. Bone Marrow Transplant 1991;8:51-8.
[98] Hsieh MH, Korngold R. Differential use of FasL- and perforin-mediated cytolytic
mechanisms by T-cell subsets involved in graft-versus-myeloid leukemia responses.
Blood 2000;96:1047-55.
[99] Jiang YZ, Kanfer EJ, Macdonald D, Cullis JO, Goldman JM, Barrett AJ. Graft-versus-
leukaemia following allogeneic bone marrow transplantation: emergence of cytotoxic T
lymphocytes reacting to host leukaemia cells. Bone Marrow Transplant 1991;8:253-8.
[100] Nishida T, Hudecek M, Kostic A, Bleakley M, Warren EH, Maloney D, et al. Development
of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell
transplant for chronic lymphocytic leukemia. Clin Cancer Res 2009;15:4759-68.
[101] Ye Z, Tang C, Xu S, Zhang B, Zhang X, Moyana T, et al. Type 1 CD8+ T cells are superior
to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, pro-
longed survival and type 1 immune modulation. Cell Mol Immunol 2007;4:277-85.
[102] Fowler DH, Breglio J, Nagel G, Hirose C, Gress RE. Allospecific CD4+, Th1/Th2 and
CD8+, Tc1/Tc2 populations in murine GVL: type I cells generate GVL and type II cells
abrogate GVL. Biol Blood Marrow Transplant 1996;2:118-25.
[103] Antin JH, Weinstein HJ, Guinan EC, McCarthy P, Bierer BE, Gilliland DG, et al. Recom-
binant human interleukin-1 receptor antagonist in the treatment of steroid-resistant
graft-versus-host disease. Blood 1994;84:1342-8.
[104] Antin JH, Weisdorf D, Neuberg D, Nicklow R, Clouthier S, Lee SJ, et al. Interleukin-1
blockade does not prevent acute graft-versus-host disease: results of a randomized,
double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in alloge-
neic bone marrow transplantation. Blood 2002;100:3479-82.
[105] Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, et al. Tumor necrosis
factor-alpha blockade for the treatment of acute GVHD. Blood 2004;104:649-54.
[106] Brown ER, Charles KA, Hoare SA, Rye RL, Jodrell DI, Aird RE, et al. A clinical study as-
sessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in
patients with advanced cancer. Ann Oncol 2008;19:1340-6.
[107] Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Narula SK, Smith SR, Roncarolo MG, et al.
Interleukin-10 dose-dependent regulation of CD4+ and CD8+ T cell-mediated graft-
versus-host disease. Transplantation 1998;66:1220-9.
[108] Atkinson K, Matias C, Guiffre A, Seymour R, Cooley M, Biggs J, et al. In vivo adminis-
tration of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage
CSF, interleukin-1 (IL-1), and IL-4, alone and in combination, after allogeneic murine
hematopoietic stem cell transplantation. Blood 1991;77:1376-82.
[109] Wu CJ, Ritz J. Induction of tumor immunity following allogeneic stem cell transplanta-
tion. Adv Immunol 2006;90:133-73.
[110] Talvensaari K, Clave E, Douay C, Rabian C, Garderet L, Busson M, et al. A broad
T-cell repertoire diversity and an efficient thymic function indicate a favorable
long-term immune reconstitution after cord blood stem cell transplantation. Blood
2002;99:1458-64.
[111] Brusic A, Wu CJ. Enhancing graft-versus-leukemia after transplant: the rise of anti-
cancer vaccines. Front Biosci 2012;17:635-55.
[112] Wu CJ, Yang XF, McLaughlin S, Neuberg D, Canning C, Stein B, et al. Detection of a
potent humoral response associated with immune-induced remission of chronic my-
elogenous leukemia. J Clin Invest 2000;106:705-14.
[113] Yang XF, Wu CJ, Chen L, Alyea EP, Canning C, Kantoff P, et al. CML28 is a broadly
immunogenic antigen, which is overexpressed in tumor cells. Cancer Res
2002;62:5517-22.
[114] Zhang W, Choi J, Zeng W, Rogers SA, Alyea EP, Rheinwald JG, et al. Graft-versus-
leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor
lymphocyte infusion. Clin Cancer Res 2010;16:2729-39.
[115] Biernacki MA, Marina O, Zhang W, Liu F, Bruns I, Cai A, et al. Efficacious immune ther-
apy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on
CML progenitor cells. Cancer Res 2010;70:906-15.
[116] Marina O, Hainz U, Biernacki MA, Zhang W, Cai A, Duke-Cohan JS, et al. Serologic
markers of effective tumor immunity against chronic lymphocytic leukemia include
nonmutated B-cell antigens. Cancer Res 2010;70:1344-55.
[117] Bellucci R, Alyea EP, Weller E, Chillemi A, Hochberg E, Wu CJ, et al. Immunologic effects
of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for
multiple myeloma. Blood 2002;99:4610-7.

323